


TEG in TRAUMA



Kerry Gunn

Department of Anaesthesia and Perioperative Medicine
Auckland City Hospital

- ❑ A **small** proportion (4%) need an **aggressive** approach to transfusion
- ❑ Systems that include fibrinogen substrates *seem* to improve outcome
- ❑ The challenge is to develop **systems** that deliver fibrinogen rapidly enough to these patients
- ❑ TEG then can help us direct fibrinogen and drugs to the patients that need it
- ❑ Unless we include POC monitoring of coagulopathy we risk replacing exsanguination with thrombosis

10 units RBC
in 4 hrs

No Transfusion

Focused Tx

DCR

10 units RBC in
24 hrs

Transfusion for massive blood loss 271

Table 1. Investigations to be performed during massive transfusions

Investigation	Target value
Haemoglobin; haematocrit	10 g/dl; 0.32
Platelet count	$> 50 \times 10^9/l$
Prothrombin time	$< 1.5 \times \text{control}$
Partial thromboplastin time	$< 1.5 \times \text{control}$
Fibrinogen	$> 0.8 \text{ g/l}$

BSCH guidelines for massive transfusion 1998




- ❑ measures **viscoelastic** properties
- ❑ incorporates input from clotting, platelets and fibrinolysis
- ❑ dynamic
- ❑ rapid results







CPAP machine no longer in PACU
Please borrow from DCCM

ROTEM





Schematic Diagram of Normal Thromboelastography Tracing



Platelet Dysfunction

TEG MONITORING PROGRAM - DETAIL OF COMPLETED CHANNEL 1 (2)

Time On: 12:38:00 pm

Date: Thu Mar 23, 2006

Time Off: 1:35:58 pm

Patient Name:

Patient Number: ON PUMP

Sample Type: Celite-Activated Whole Blood



10 mm scale	SP (mm)	R (mm)	K (mm)	MA (mm)	Ang (deg)	LY30 (%)	LY60 (%)
Pt:	13.5	14.5	10.0	39.0	49.0		
NR:		10-14	3-6	59-68	54-67		

ENTER to exit, F6 prints large, F7 prints small, LEFT or RIGHT to scroll

After Platelet Transfusion

TEG MONITORING PROGRAM - DETAIL OF COMPLETED CHANNEL 6 (1)

Time On: 3:02:04 pm

Date: Thu Mar 23, ---

Time Off: 4:16:37 pm

Patient Name: _____

Patient Number: WITH PLT

Sample Type: Celite-Activated Whole Blood



TEG Index: +3.21
Normal Range: -2.0 to +2.0

10 mm scale	SP (mm)	R (mm)	K (mm)	MA (mm)	Ang (deg)	LY30 (%)	LY60 (%)
Pt:	7.5	8.5	2.5	72.0	71.5	0.5	
NR:		10-14	3-6	59-68	54-67		

ENTER to exit, F6 prints large, F7 prints small, LEFT or RIGHT to scroll

J. Hirsch,¹ T. Wendt,¹ P. Kuhly² and W. Schaffartzik³¹ Senior HouseDepartment of An
the Free University**Can RapidTEG Accelerate the Search for Coagulopathies in the Patient With Multiple Injuries?**

Victor Jager, MS, Heinz Zimmermann, MD, and Aristomenis K. Exadaktylos, MD

TI
Ti

Hypothesis: Early recognition of coagulopathy may improve the care of patients with multiple injuries. Rapid thrombostography (RapidTEG) is a new variant of thrombostography (TEG), in which coagulation is initiated by the addition of protein tissue factor. The kinetics of coagulation and the time of measurement were compared for two variants of TEG—RapidTEG and conventional TEG, in which coagulation was initiated with kaolin. The measurements were performed on blood samples from 20 patients with

multiple injuries. The RapidTEG results were also compared with conventional measurements of blood coagulation. The mean time for the RapidTEG test was 19.2 ± 3.1 minutes (mean \pm SD), in comparison with 28.9 ± 4.3 minutes for kaolin TEG and 34.1 ± 14.5 minutes for conventional coagulation tests. The mean time for the RapidTEG test was 30.6 ± 5.72 minutes, in comparison with 41.8 ± 5.86 minutes for kaolin TEG and 64.9 ± 18.8 for conventional coagulation tests—measured from admission of the patients to the re-

suscitation bay until the results were available. There were significant correlations between the RapidTEG results and those from kaolin TEG and conventional coagulation tests. RapidTEG is the most rapid available test for providing reliable information on coagulopathy in patients with multiple injuries. This has implications for improving patient care.

Key Words: Thrombostography, Traumatic coagulopathy, Multiple injuries, tissue factor.

J Trauma. 2009;66:1253–1257.

**Control Resuscitation on mortality
in multiple injuries: a before and after study**

J. Hirsch, MSc, H. Zimmermann, MD, and Aristomenis K. Exadaktylos, MD

BJA

**clopidogrel and
patients measured
TEG using
TEGTM**

Anesthesia, and Critical Care

**TEG in the
ER**

Holcomb, MD

Linda Shore-Lessers
Sanjeev Francis, BS*

Departments of *Anesthes

T. C. Collyer^{1a}, D. J. Gray², R. Sandhu², J. Berridge³ and G. Lyons²¹Academic Unit of Anaesthesia, Royal Perth Hospital, Perth, Australia. ²Department of Anaesthesia, St James's University Hospital, Leeds, UK. ³Department of Anaesthesia, Leeds General Infirmary, Leeds, UK

*Corresponding author. E-mail: tomcollyer@doctors.org.uk

HEAD-TO-HEAD

The TEG[®] vs the ROTEM[®] thromboelastometry systemsG. N. B. Jackson,¹ K. J. Ashpole² and S. M. Yentis³¹Fellow, ²Locum Consultant, ³Consultant, Magill Department of Anaesthetics and Westminster Hospital, London, UK**Does Thromboelastography Predict Postoperative Thromboembolic Events? A Systematic Review of the Literature**

Yue Dai, MB, MSc*

Anna Lee, PhD*

Lester A. H. Critchley, MD*

Paul F. White, PhD, MD†

BACKGROUND: Since thromboelastography (TEG) can detect hypercoagulable states, it is a potentially useful test for predicting postoperative thromboembolic complications. Therefore, we performed a systematic review of the literature to evaluate the accuracy of TEG in predicting postoperative thromboembolic events.**METHODS:** PUBMED and EMBASE electronic databases were searched by two independent investigators to identify prospective studies involving adult patients undergoing operative procedures in which a TEG test was performed perioperatively and outcomes were measured by reference standards. The quality of included studies was assessed and measures of diagnostic test accuracy were

Does TEG **predict these
coagulation changes in
haemorrhagic and shocked
trauma patients?**

YES.....But so do other indices




TABLE 6: Prediction of transfusion by CCT, Rapid TEG^{*}, and Kaolin TEG^{*}.

		Cut-offs	Sensitivity	Specificity	PPV	NPV	AUC
Single indicator							
INR		>1.2	38%	88%	57%	77%	73%
INR		>1.5	19%	96%	67%	74%	73%
aPTT (sec)		>60.0	5%	98%	50%	69%	74%
Fibrinogen (g/L)		<3.0	90%	48%	43%	92%	74%
Thrombin time [sec]		>13.2	48%	73%	45%	75%	53%
Rapid K (min)		>1.8	68%	78%	61%	83%	79%
Kaolin K (min)		>1.7	68%	59%	46%	78%	67%
Rapid α -Angle (deg)		<74.7	84%	57%	49%	88%	77%
Kaolin α -Angle (deg)		<58.5	72%	61%	47%	82%	66%
Rapid MA (mm)		<59.6	68%	80%	63%	83%	75%
Kaolin MA (mm)		<58.4	56%	88%	70%	80%	70%
Rapid TMA (min)		>17.3	76%	57%	46%	83%	69%
Kaolin TMA (min)		>24.7	64%	63%	46%	78%	58%
Rapid G (d/sc)		<7374	68%	78%	61%	83%	73%
Kaolin G (d/sc)		<7073	56%	88%	70%	80%	70%
Combined indicators							
α -Angle + Heart Rate	Rapid α -Angle (deg)	<75	84%	75%	62%	90%	—
	Heart Rate (bpm)	>75					
α -Angle + Hct	Rapid α -Angle (deg)	<75	88%	73%	61%	93%	—
	Hct (%)	<41					

* Cut-offs determined by the data.

Can the TEG **explain the
coagulation changes in
haemorrhagic and shocked
trauma patients?**


- ❑ Usually has an adequate Thrombin burst
- ❑ Fibrinogen levels are reduced
- ❑ Fibrin laydown and cross-bridging is impaired
- ❑ Fibrinolysis is increased



Can TEG **direct product
treatment in haemorrhagic and
shocked trauma patients?**

- ❑ **Most of the benefit in TEG in improving blood management outside trauma is in**
 - ❑ **Stopping** blood product use when it isn't required
 - ❑ **Targeting** specific product use when a defect exists (as opposed to a reduced conc of something)

ADHB Adult Massive Transfusion Protocol (MTP)



The place of TEG?

Appendix 1 Thrombelastography (TEG) treatment algorithm for patients with ongoing bleeding

TEG Parameter	Treatment
R 11–14 min	2 × FFP or 10 ml/kg
R > 14 min	4 × FFP or 20 ml/kg
MA 46–50 mm	1 platelet concentrate
MA < 46 mm	2 platelet concentrates
Angle < 52	2 × FFP or fibrinogen
Ly30 > 8%	Antifibrinolytics

R, R-time, minutes; MA, maximum amplitude; Ly30, lysis in percent 30 min after MA is reached; FFP, fresh-frozen plasma.

One platelet concentrate pooled from the buffy-coat from four donors.



Johanson Vox Sanguinis 96 111-118

Table 1 Recommended TEG algorithm for goal-directed therapy of bleeding patients in the Capital Region of Denmark

TEG parameter*	Coagulopathy	Intervention
R >10 min	Coagulation factors ↓	FFP 10–20 ml/kg (if FFP is without clinical efficacy, consider cryoprecipitate 3–5 ml/kg)
Angle <52 °	Hypofibrinogenemia?	→ Functional Fibrinogen (FF) analysis
MA <49 mm and MA_{FF} <14 mm	Fibrinogen ↓	FFP 20–30 ml/kg /
Fibrinogen konc. 25–50 mg/kg / Cryoprecipitate 5 ml/kg		
MA <49 mm and MA_{FF} >14 mm	Platelets ↓	Platelets 5–10 ml/kg
Ly30 >8%	Primary hyperfibrinolysis	Tranexamic acid 1–2 g IV (adults)
Children 10–20 mg/kg IV		
Ly30 >8% and Angle and/or MA ↑↑	Reactive hyperfibrinolysis	Tranexamic acid contraindicated
Difference in R >2 min between st-TEG and hep-TEG	Heparinization	Protamine sulphate or FFP 20–30 ml/kg

R, Reaction time; Angle, α-angle; MA, Maximum amplitude; MA_{FF}, Maximum amplitude by Functional Fibrinogen[®] analysis; Ly30, Lysis after 30 min; st-TEG, standard TEG; hep-TEG, heparinase TEG.

*Reference values (Haemonetics Corp.): R 3–8 min, Angle 55–78 °, MA 51–69 mm, Ly30 0–8%, MA_{FF}=14–24 mm.

RESEARCH


Open Access

Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM®)-guided administration of fibrinogen concentrate and prothrombin complex concentrate


Herbert Schöchl^{1,2}, Ulrike Nienaber³, Georg Hofer¹, Wolfgang Voelckel¹, Csilla Jambor⁴, Gisela Scharbert⁵, Sibylle Kozek-Langenecker⁵ and Cristina Solomon^{*6}

- Trauma patients receiving >5 units RBCs
- fibTEM guided therapy if <10mm
- 131 patients
- 128 received fibrinogen, 98 patient received PCC

EXTEM




FIBTEM



Trauma flowsheet in Innsbruck

Figure 1 Algorithm for immediate effective therapy of trauma-induced coagulopathy as advocated by the authors and implemented at the University Hospital Innsbruck, Austria




HES, hydroxyethyl starch solutions; RBC, red blood cell.

Electron microscopic scan of a $\times 2000$ magnified blood clot.


- fibTEM $> 10\text{mm}$

- Fibrinogen $> 1.5\text{-}2.0\text{ g/L}$


undiluted




65% haemodiluted



Post fibrinogen
administration






5 ml = 500mg
Cyklokapron®
100mg/ml
Tranexamic acid
for intravenous
injection or infusion
Do not store above 25°C
Protect from freezing




CYKLOKAPRON®
100mg/ml
TRANEXAMIC ACID
Pfizer
5 ml = 500 mg
Pfizer, Inc. (USA) and other countries. www.pfizer.com

Fibrinolysis on a TEG?



TEG 30 mins after TXA 1G



- ❑ TEG is a more intuitive coagulation test for replacement of factors in bleeding
- ❑ It has the potential to focus on better prediction of TIC
- ❑ It has the potential to increase our understanding of TIC
- ❑ It may be the tool to move us to MTP 2.0